109.47 0.00 (0.00%)
After hours: 4:30PM EST
|Bid||109.59 x 800|
|Ask||110.00 x 800|
|Day's Range||106.75 - 109.65|
|52 Week Range||82.59 - 109.65|
|Beta (5Y Monthly)||0.84|
|PE Ratio (TTM)||20.55|
|Earnings Date||Jan 29, 2020|
|Forward Dividend & Yield||2.12 (1.97%)|
|Ex-Dividend Date||Jan 12, 2020|
|1y Target Est||109.60|
Quest Diagnostics (NYSE: DGX), the leading provider of diagnostic information services, and Memorial Hermann Health System, a leading not-for-profit health system that includes 17 hospitals and more than 300 care delivery sites in the Greater Houston region, today announced a multi-pronged, long-term collaboration intended to broaden access to innovative, high-value laboratory services for providers and patients in Greater Houston.
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has acquired Blueprint Genetics in an all-cash equity transaction. Blueprint Genetics is a leading specialty genetic testing company with deep expertise in gene variant interpretation based on next generation sequencing (NGS) and proprietary bioinformatics. Together, Quest and Blueprint Genetics will broaden access to actionable insights in genetic and rare diseases, improving patient care and pharmaceutical drug research and development. Financial terms of the transaction were not disclosed.
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been selected as one of FORTUNE's World's Most Admired Companies in 2020 for the sixth consecutive year.
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2019 results on Thursday, January 30, 2020, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
Today we'll look at Quest Diagnostics Incorporated (NYSE:DGX) and reflect on its potential as an investment. To be...
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 38th Annual J. P. Morgan Healthcare Conference in San Francisco. Steve Rusckowski, Chairman, President and CEO and Mark Guinan, Executive Vice President and CFO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Tuesday, January 14, 2020 at 7:30 p.m. Eastern Time. Mr. Rusckowski and Mr. Guinan also will participate in a Q&A; session moderated by the host analyst.
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]
In 2012 Steve Rusckowski was appointed CEO of Quest Diagnostics Incorporated (NYSE:DGX). This analysis aims first to...
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $800 million aggregate principal amount of its 2.950% senior notes due 2030 under the Quest Diagnostics' shelf registration statement.
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the proposed offering of senior unsecured notes of Quest Diagnostics Incorporated ("Quest"). There are no changes to Moody's existing ratings of Quest including the Baa2 senior unsecured long-term rating. Further, Quest has a long track record of maintaining modest financial leverage and generating stable cash flows, which Moody's expects will continue.
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
Today I will take a look at Quest Diagnostics Incorporated's (NYSE:DGX) most recent earnings update (30 September...
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SECAUCUS, N.J. , Nov. 20, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly ...
Other Company Research Demonstrates the Value of Diagnostic Insights in Early Cardiovascular Disease Detection in Clinical and Workplace Settings SECAUCUS, N.J. , Nov. 14, 2019 /PRNewswire/ -- A laboratory ...
SECAUCUS, N.J., Nov. 5, 2019 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced that it has achieved Gold status in the American Heart Association's 2019 Workplace Health Achievement Index, ranking the company's workplace health initiative among the best in the nation. 2019 marks the second year in a row that Quest has earned this distinction. The Index uses science-based best practices to evaluate the overall quality and comprehensiveness of workplace health programs.
Does the November share price for Quest Diagnostics Incorporated (NYSE:DGX) reflect what it's really worth? Today, we...